Buserelin
DB06719
Approved Indication
Buserelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.
2
Targets
0
Resistance Mutations
0
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Buserelin stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). Buserelin desensitizes the GnRH receptor, reducing the amount of gonadotropin. In males, this results in a reduction in the synthesis and release of testosterone. In females, estrogen secretion is inhibited. While initially, there is a rise in FSH and LH levels, chronic administration of Buserelin results in a sustained suppression of these hormones.
Details
DrugBank ID
DB06719 ↗
Approval Date
—
Molecular Weight
— g/mol
Drug Class
Other
ATC Codes
L02AE01
Synonyms
D-Ser(Tbu)6EA10LHRH, Etilamide, Tiloryth
ChEMBL
CHEMBL1909304 ↗